Literature DB >> 23062542

Cardiac resynchronization and quality of life in patients with minimally symptomatic heart failure.

Peter J Veazie1, Katia Noyes, Qinghua Li, W Jackson Hall, April Buttaccio, Kelly Thevenet-Morrison, Arthur J Moss.   

Abstract

OBJECTIVES: This study compared the quality of life (QOL) of patients with cardiac resynchronization therapy (CRT) and an implantable cardioverter-defibrillator (ICD) to patients with an ICD only.
BACKGROUND: CRT with ICD is associated with a reduction in heart failure risk among minimally symptomatic patients. It is unknown whether this improves QOL.
METHODS: This study uses the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) data. The MADIT-CRT enrolled 1,820 patients at 110 centers across 14 countries. Patients had ischemic cardiomyopathy (New York Heart Association [NYHA] functional class I or II) or nonischemic cardiomyopathy (NYHA functional class II only), sinus rhythm, an ejection fraction of 30% or less, and prolonged intraventricular conduction with a QRS duration of 130 ms or more. QOL was evaluated on the 1,699 patients with baseline and follow-up measures using the Kansas City Cardiomyopathy Questionnaire (KCCQ). Six dimensions (Physical Limitation, Symptom Stability, Symptom Frequency, Symptom Burden, Quality of Life, and Social Limitations) and 3 summary scores (Total Symptom, Clinical Summary, and Overall Summary) were analyzed.
RESULTS: During an average follow-up of 2.4 years, the CRT-ICD group had greater improvement than the ICD-only group on all KCCQ measures (p < 0.05 on each scale). These differences were significant among patients with left bundle branch block conduction disturbance (n = 1,204, p < 0.01 on each scale), but not among patients without left bundle branch block (n = 494).
CONCLUSIONS: Compared with patients with ICD only, CRT-ICD is associated with greater improvement in QOL among relatively asymptomatic patients, specifically among those with left bundle branch conduction disturbance.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23062542     DOI: 10.1016/j.jacc.2012.06.054

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  18 in total

1.  Optimizing heart failure treatment following cardiac resynchronization therapy.

Authors:  Anders Jorsal; Kasper Pryds; John J V McMurray; Henrik Wiggers; Anders Sommer; Jens Cosedis Nielsen; Roni Ranghøj Nielsen
Journal:  Clin Res Cardiol       Date:  2019-09-26       Impact factor: 5.460

2.  Assessing the impact of heart failure therapeutics on quality of life and functional capacity.

Authors:  Eldrin F Lewis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-08

Review 3.  Assessing quality-of-life outcomes in cardiovascular clinical research.

Authors:  Daniel B Mark
Journal:  Nat Rev Cardiol       Date:  2016-02-18       Impact factor: 32.419

4.  Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.

Authors:  Alvin Chandra; Eldrin F Lewis; Brian L Claggett; Akshay S Desai; Milton Packer; Michael R Zile; Karl Swedberg; Jean L Rouleau; Victor C Shi; Martin P Lefkowitz; Tzvetana Katova; John J V McMurray; Scott D Solomon
Journal:  JAMA Cardiol       Date:  2018-06-01       Impact factor: 14.676

5.  Health-related quality of life assessment in children followed in a cardiomyopathy clinic.

Authors:  Melanie R Friess; Bradley S Marino; Amy Cassedy; Ivan Wilmot; John L Jefferies; Angela Lorts
Journal:  Pediatr Cardiol       Date:  2014-10-07       Impact factor: 1.655

6.  Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION.

Authors:  Nancy Luo; Christopher M O'Connor; Lauren B Cooper; Jie-Lena Sun; Adrian Coles; Shelby D Reed; David J Whellan; Ileana L Piña; William E Kraus; Robert J Mentz
Journal:  Eur J Heart Fail       Date:  2018-08-31       Impact factor: 15.534

7.  Effect of Carillon Mitral Contour System on patient-reported outcomes in functional mitral regurgitation: an individual participant data meta-analysis.

Authors:  Muhammad Shahzeb Khan; Tim Friede; Stefan D Anker; Javed Butler
Journal:  ESC Heart Fail       Date:  2021-03-30

Review 8.  Drug therapy for heart failure in older patients-what do they want?

Authors:  Donah Zachariah; Jacqueline Taylor; Nigel Rowell; Clare Spooner; Paul R Kalra
Journal:  J Geriatr Cardiol       Date:  2015-03       Impact factor: 3.327

Review 9.  Patient-Reported Outcomes in Patients with Cardiomyopathy.

Authors:  Raul Angel Garcia; Mary C Benton; John A Spertus
Journal:  Curr Cardiol Rep       Date:  2021-06-14       Impact factor: 3.955

10.  Quantification of survival gain from cardiac resynchronization therapy: nonlinear growth with time, and greater gain in low-risk patients, make raw trial data an underestimate of real-world behavior.

Authors:  Judith A Finegold; Claire E Raphael; Wayne C Levy; Zachary Whinnett; Darrel P Francis
Journal:  J Am Coll Cardiol       Date:  2013-09-04       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.